| |
| | BioSpace News for |
 | | EpiGenesis gains access to state-of-the-art antisense chemistry and a patent portfolio that will dramatically reduce the time required to further develop its proprietary RASONs (respirable antisense oligonucleotides) to treat a wide range of respiratory diseases. |
 | | EpiGenesis Pharmaceuticals Inc., today announced a development and licensing agreement with Taisho Pharmaceuticals Co. Ltd., of Tokyo, for access to the company's respiratory discovery and development platform, including EPI-2010, for asthma. |
 | | EpiGenesis Pharmaceuticals Inc., today announced that it has begun a randomized, double-blind, first-in-man, Phase I study to assess tolerability and pharmacokinetics of inhaled EPI-2010 for asthma. |
| www.biospace.com /news_company.cfm?CompanyID=3255 (869 words) |
|